Clinical trial

#AI #Clinical trial #Thermo Fisher Scientific

Thermo Fisher announces collaboration with OpenAI

Biotechnology company Thermo Fisher has announced plans to increase the impact of its growth strategy using artificial intelligence (AI) with OpenAI.  Thermo Fisher believes the collaboration with OpenAI will help to improve the speed and success of drug development, enabling customers to get medicines to patients faster and more cost… Read More

#Business & Investment #News

Herpes virus cells
#Clinical trial #Herpes virus

Aicuris announces Phase III trial results of HSV treatment

Biotechnology company Aicuris Anti-Infective Cures AG has announced its Phase III trial of pritelivir, a treatment for Herpes Simplex Virus (HSV), has reached its primary endpoint.  The first-in-class helicase primase inhibitor met its primary endpoint of superiority (p=0.0047) in lesion healing in HSV patients receiving treatment up to 28 days. Statistical superiority… Read More

#News

Leukaemia
#Acute Myeloid Leukaemia #Blood cancer #Cancer research #Clinical trial

Amphista Therapeutics nominates AML candidate for clinical trial

Biotechnology company Amphista Therapeutics has announced its nomination of AMX-883 as its first clinical development candidate for the treatment of acute myeloid leukaemia (AML).  AMX-883 is a potent, selective and orally bioavailable degrader of BRD9. Leveraging Amphista’s Eclipsys platform and proprietary Targeted Glue technology, AMX-883 induces the… Read More

#News

#AI #Clinical trial

AI creating ‘measurable gains’ in clinical trials, new data reveals

Over 70% of artificial intelligence (AI) users in clinical trials see measurable gains in study speed, data analytics brand Medidata has revealed.  The findings come from a new global research report, ‘The State of AI In Clinical Trials: Today and Tomorrow’, which investigates how AI is redesigning… Read More

#News

Laboratory research
#Clinical trial #Orexa

Positive interim data announced in clinical trial of POI treatment

Life sciences company Orexa has announced positive interim data for its Phase II trial evaluating ORE-001, a treatment for the prevention of post-operative ileus (POI) in patients undergoing major abdominal surgery.  Interim analysis was conducted after 40 patients were randomised. The data demonstrated that ORE-001 could be… Read More

#News

Screening patient for AMD
#AMD #Clinical trial #Complement Therapeutics #FDA #Gene therapy #Geographic atrophy #Ophthalmology

FDA clears gene therapy trial in geographic atrophy

The US Food and Drug Administration (FDA) has cleared Complement Therapeutics’ Investigational New Drug (IND) application for CTx001, the company’s lead gene therapy candidate.   The IND clearance enables initiation of the Opti-GAIN Phase I/II clinical trial in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).   CTx001… Read More

#News #Regulatory

Myeloma cells
#Clinical trial #Myeloma

Phase I/IIa trial of myeloma treatment HDP-101 underway

The Phase I/IIa trial of HDP-101, an ATAC candidate for the treatment of relapsed or refractory multiple myeloma, is underway, biotech company Heidelberg Pharma has announced.  The Phase I/IIa trial will evaluate Cohort 9 of HDP-101 after the Safety Review Committee (SRC) confirmed that the 140 µg/kg dose… Read More

#News

Multiple myeloma
#Clinical trial #Myeloma

ACT appointed to conduct Phase IIa trial of POLB 001 

Specialist blood cancer trials organisation Accelerating Clinical Trials Limited (ACT) has signed an agreement with biopharmaceutical company Poolbeg Pharma to conduct the Phase IIa clinical trial of POLB 001.  The Phase IIa first-in-patient open-label, single-arm trial is titled TOPICAL (Trial of Prevention of ImmunoCytokine Adverse events in Myeloma). Read More

#News

Influenza
#Cidara #Clinical trial #Influenza

Phase III trial of flu preventative CD388 accelerated  

The Phase III study of CD388, a non-vaccine preventative of seasonal flu, has been accelerated by six months, biotechnology company Cidara Therapeutics has announced.  The planned Phase III study will be a global, multicentre, randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single… Read More

#News

Researcher in lab
#Acadia Pharmaceuticals #Clinical trial #Phase III trial #Rare disease

Acadia cancels development of intranasal carbetocin in rare disease

Acadia Pharmaceuticals has announced that its Phase III COMPASS PWS trial evaluating intranasal carbetocin (ACP-101) in patients with hyperphagia in Prader-Willi syndrome (PWS) did not meet its primary endpoint.  The treatment did not demonstrate a statistically significant improvement over placebo on the study’s primary endpoint, change from… Read More

#News

#Clinical trial #Treatment-resistant depression

Positive data published on BPL-003 for patients with TRD

Biopharmaceutical company atai Life Sciences has announced positive data from a proof-of-concept study investigating a two-dose induction regimen of BPL-003 (intranasal mebufotenin benzoate) in patients with treatment-resistant depression (TRD).  The open-label Phase IIa study (NCT05660642) enrolled 13 patients with TRD who were not on… Read More

#News

#Clinical trial #Drug discovery #Gene therapy #Neuroscience #Parkinson's

AskBio begins second phase of gene therapy trial for Parkinson’s  

The first European patients have been randomised in a Phase II gene therapy clinical trial for Parkinson’s disease (PD), AskBio has announced.   The REGENERATE-PD clinical trial is evaluating the safety and efficacy of AskBio’s investigational gene therapy AB-1005 and will enrol approximately 87 patients across clinical trial… Read More

#Editor's Choice #News

Subcutaneous injection
#Clinical trial

First patient dosed in Phase I trial of antibody-drug conjugate TJ101

The first patient has been dosed in the Phase I clinical trial of the antibody-drug conjugate (ADC) TJ101, Phrontline Biopharma has announced. The Phase I study of TJ101, targeting EGFR/B7-H3, will evaluate its safety, tolerability, pharmacokinetics, and preliminary antitumour activity across multiple solid tumour types. The study design… Read More

#News

Laboratory research
#Clinical trial #Faron Pharmaceuticals #Oncology #Phase II trial

Faron reports 43% complete remission rate in MDS

Faron Pharmaceuticals has announced an increase in the complete remission (CR) rate in patients with frontline or treatment-naïve high-risk myelodysplastic syndrome (HR-MDS), based on updated efficacy data from its Phase I/II BEXMAB trial.  According to the investigator-assessed response using IWG 2006 criteria, as per protocol, the CR… Read More

#News

Bubonic plague bacteria
#Bacteria #Clinical trial #Pandemic #Pandemic prevention

First clinical evidence for bubonic plague treatment

Researchers from the UK and Madagascar, in collaboration with Madagascar’s health services and national plague programme, have conducted the world’s first rigorous clinical trial of treatments for bubonic plague.  The IMASOY trial provides the first robust evidence of the efficacy and safety of two common treatment regimens. … Read More

#News